Sentiment for Johnson & Johnson (NYSE:JNJ)
Johnson & Johnson (NYSE:JNJ) institutional sentiment increased to 0.97 in 2018 Q2. Its up 0.04, from 0.93 in 2018Q1. The ratio increased, as 818 investment managers increased or started new equity positions, while 842 sold and reduced their stakes in Johnson & Johnson. The investment managers in our partner’s database reported: 1.84 billion shares, up from 1.71 billion shares in 2018Q1. Also, the number of investment managers holding Johnson & Johnson in their top 10 equity positions decreased from 503 to 415 for a decrease of 88. Sold All: 36 Reduced: 806 Increased: 704 New Position: 114.
Johnson & Johnson, together with its subsidiaries, researches and develops, makes, and sells various products in the health care field worldwide. The company has market cap of $388.61 billion. It operates through three divisions: Consumer, Pharmaceutical, and Medical Devices. It has a 254.65 P/E ratio. The Consumer segment offers baby care products under the JOHNSONÂ’S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSONÂ’S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
The stock increased 0.15% or $0.22 during the last trading session, reaching $144.9. About 4.47M shares traded. Johnson & Johnson (NYSE:JNJ) has risen 5.07% since November 14, 2017 and is uptrending. It has underperformed by 10.55% the S&P500.
Analysts await Johnson & Johnson (NYSE:JNJ) to report earnings on January, 22. They expect $1.95 EPS, up 12.07 % or $0.21 from last year’s $1.74 per share. JNJ’s profit will be $5.23 billion for 18.58 P/E if the $1.95 EPS becomes a reality. After $2.05 actual EPS reported by Johnson & Johnson for the previous quarter, Wall Street now forecasts -4.88 % negative EPS growth.
Robert Wood Johnson Foundation holds 100% of its portfolio in Johnson & Johnson for 13.00 million shares. Cincinnati Indemnity Co owns 25,000 shares or 12.4% of their US portfolio. Moreover, Pettee Investors Inc. has 11.06% invested in the company for 144,647 shares. The Pennsylvania-based Glenmede Trust Co Na has invested 10.86% in the stock. Armstrong Henry H Associates Inc, a Pennsylvania-based fund reported 503,662 shares.
Since January 1, 0001, it had 0 buys, and 4 selling transactions for $11.99 million activity.
Johnson & Johnson (NYSE:JNJ) Ratings Coverage
Ratings analysis reveals 43% of Johnson & Johnson’s analysts are positive. Out of 7 Wall Street analysts rating Johnson & Johnson, 3 give it “Buy”, 0 “Sell” rating, while 4 recommend “Hold”. The lowest target is $129 while the high is $16000. The stock’s average target of $148.50 is 2.48% above today’s ($144.9) share price. JNJ was included in 8 notes of analysts from May 17, 2018. Credit Suisse maintained Johnson & Johnson (NYSE:JNJ) rating on Wednesday, October 17. Credit Suisse has “Outperform” rating and $152 target. The firm earned “Neutral” rating on Monday, October 22 by Citigroup. Leerink Swann maintained the shares of JNJ in report on Thursday, May 17 with “Buy” rating. The stock has “Outperform” rating by Raymond James on Wednesday, October 17. As per Tuesday, June 12, the company rating was maintained by Credit Suisse. Morgan Stanley maintained the shares of JNJ in report on Thursday, October 11 with “Equal-Weight” rating. The firm has “Neutral” rating given on Thursday, July 12 by Goldman Sachs.